Scarica l'app Stockscreener
23.72
6.08%
1.36
Dopo l'orario di chiusura:
23.66
-0.06
-0.25%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$22.36
Aprire:
$22.39
Volume 24 ore:
13.87M
Relative Volume:
1.20
Capitalizzazione di mercato:
$9.27B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-2.7171
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
-4.24%
1M Prestazione:
-13.71%
6M Prestazione:
-8.06%
1 anno Prestazione:
-37.99%
Intervallo 1D:
$22.28
$23.94
Intervallo di 1 settimana:
$22.28
$25.33
Portata 52W:
$22.28
$48.92
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
23.72 | 8.74B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
How Recent Developments Are Rewriting the Story for Moderna - Yahoo Finance
First-Ever Human H5N5 Case Turns Fatal In Washington StateModerna (NASDAQ:MRNA), Pfizer (NYSE:PFE) - Benzinga
Leerink Partners Issues Positive Forecast for Moderna (NASDAQ:MRNA) Stock Price - MarketBeat
Royal Bank Of Canada Lowers Moderna (NASDAQ:MRNA) Price Target to $25.00 - MarketBeat
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates - Erie Times-News
Moderna stock remains Buy at UBS as analyst sees strong pipeline progress - Investing.com Canada
Clover Health, GoodRx, Moderna, UFP Technologies, and Masimo Shares Are Soaring, What You Need To Know - The Globe and Mail
Moderna (NASDAQ:MRNA) Sets New 12-Month LowHere's Why - MarketBeat
Five Things To Know From Moderna’s Analyst Day - Citeline News & Insights
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - Tallahassee Democrat
Piper Sandler Lowers Moderna (MRNA) Price Target to $63 | MRNA Stock News - GuruFocus
Moderna (MRNA) Rating Maintained, Price Target Lowered by RBC Ca - GuruFocus
MRNA: Leerink Partners Raises Price Target, Maintains Underperfo - GuruFocus
Piper Sandler Adjusts Price Target on Moderna to $63 From $69, Maintains Overweight Rating - MarketScreener
Leerink Partners Adjusts Price Target on Moderna to $18 From $15, Maintains Underperform Rating - MarketScreener
RBC Cuts Price Target on Moderna to $25 From $28, Keeps Sector Perform Rating - MarketScreener
Moderna Cans 3 mRNA Vaccines, Secures $1.5B Loan in Quest for 10% Growth - BioSpace
$1.5 Billion Loan Aims to Help Moderna Grow and Invest in Research - MarketScreener
Rx Rundown: Johnson & Johnson, Avadel Pharmaceuticals, Moderna and more - Medical Marketing and Media
Analyst recommendations: Block, Palo Alto Networks, Biogen, Moderna, Netflix… - MarketScreener
22,410 Shares in Moderna, Inc. $MRNA Acquired by Catalyst Funds Management Pty Ltd - MarketBeat
Is Moderna Inc. stock trading near support levelsMarket Growth Summary & Free High Accuracy Swing Entry Alerts - newser.com
Walmart, Intuit, The Gap, SanDisk And Moderna: Why These 5 Stocks Are On Investors' Radars Today - inkl
Health Care Down, But not by Much, Amid Deal Activity -- Health Care Roundup - MarketScreener
IR Insights: Recapping Our 2025 Analyst Day - Moderna
Moderna Secures $1.5B Credit Facility As It Seeks To Pivot Away From Vaccines - Stocktwits
Moderna stock hits 52-week low at 23.04 USD By Investing.com - Investing.com India
Moderna stock hits 52-week low at 23.04 USD - Investing.com
Moderna projects 10% growth next year; lifts outlook for year-end liquidity - MSN
Moderna secures $1.5B lifeline as it looks to break even in 2028 - BioPharma Dive
Moderna promises pipeline progress and healthy growth - The Pharma Letter
Moderna (MRNA) Unveils Pipeline Progress and Strategic Updates a - GuruFocus
Moderna gets breathing room with $1.5 billion loan from Ares - The Boston Globe
Moderna to onshore drug product manufacturing to Massachusetts - Yahoo Finance
Moderna Trims Pipeline and Takes On $1.5 Billion Loan as Cash Worries Loom - Barron's
Moderna : Presentation (Moderna 2025 Analyst Day FINAL PDF 48 ) - MarketScreener
Moderna to Host Investor Event – Analyst Day - Battle Creek Enquirer
Moderna takes $1.5 billion loan, expects 10% revenue growth next year - The Mighty 790 KFGO
Moderna (MRNA) Developments: Vaccine Approvals and Strategic Adjustments - GuruFocus
Moderna (MRNA) Projects Revenue Growth and Strategic Investments - GuruFocus
Moderna (MRNA) Reveals Strategic Plans for Growth and Innovation - GuruFocus
Moderna (MRNA) Targets Major Vaccine Expansion by 2028 - GuruFocus
Moderna (MRNA) Optimizes Global Manufacturing for Future Growth - GuruFocus
Moderna secures $1.5 billion credit facility from Ares Management By Investing.com - Investing.com Australia
Moderna secures $1.5 bln loan, targets up to 10% rev growth in 2026 - MarketScreener
Moderna outlines growth strategy targeting 10% revenue increase in 2026 - Investing.com
Moderna (MRNA) Projects Revenue Growth and Strategic Financial M - GuruFocus
Moderna (MRNA) Unveils Strategic Growth Plans and Pipeline Updates - GuruFocus
Moderna (MRNA) Secures $1.5 Billion Loan to Enhance Financial Fl - GuruFocus
Moderna Announces Pipeline Progress and Strategy Update - TipRanks
Moderna, Inc. Announces Pipeline and Strategy Updates at Analyst Day - TradingView
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):